Pacgen, XPhase Pharmaceuticals Inc. deal

Infectious and inflammatory disease company Pacgen completed its previously announced acquisition of XPhase for 3 million shares or C$150,000 (US$135,690) based on Pacgen's close of C$0.05 on Aug. 12,...